JRP Bio completes phase 1 trial of SH003 with docetaxel
Third phase 1 trial after low-dose and high-dose monotherapy
JRP Bio (Jaein R&P Co., Ltd.) announced that it has completed a phase 1 trial of SH003 combined with docetaxel — its third phase 1 trial after monotherapy in solid tumors (2019) and high-dose monotherapy (2022).
The trial used a multi-center, open-label, dose-escalation design in patients with breast and lung cancer, and the results were published in Integrative Cancer Therapies (2025).
Building on the results, the company prepared a phase 2a combination trial in non-small cell lung cancer, which the MFDS approved in August 2025.
About JRP Bio
JRP Bio (Jaein R&P Co., Ltd.) standardizes Korean medicine formulas and natural products, builds the evidence behind them, and secures approval to turn them into products people actually use. JRP stands for “Journey from Research to People.” The company received Korea's first IND for an oral botanical anticancer candidate, SH003, and holds 14 granted Korean patents and 42 SCI(E) publications.
Media contact
- Email bs@jrpbio.com
- Phone +82-2-6925-5568